A Single Group Treatment, Phase 2 study to investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam administered by intra-venous infusion over 2 hours in Male or Female Participants from birth to less than 18 years of age hospitalized with complicated urinary tract infections (cUTI) including Acute Pyelonephritis (AP).EMA Decision number of Paediatric Investigation Plan: P/0093/2019.
A Phase 3, Randomized, Double-Blind, Multi-Center Study toEvaluate the Efficacy, Safety, and Tolerability of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatmentof Complicated Urinary Tract Infections, Including AcutePyelonephritis, in Adults
Randomized, Double-Blind, Multi-Center Study of Cefepime/AAI101 in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis
100 Clinical Results associated with Allecra Therapeutics SAS
0 Patents (Medical) associated with Allecra Therapeutics SAS
100 Deals associated with Allecra Therapeutics SAS
100 Translational Medicine associated with Allecra Therapeutics SAS